


AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com

(Rs. in Lakhs)

STATEMENT OF STAND ALONE/CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2014

PART I	Particulars	Stand alone					Consolidated				
		Three months ended		Nine months ended		Year Ended	Three months ended		Nine months ended		Year Ended
		31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.03.2014
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations										
	(a) Net sales/Income from operations (Net of excise duty)	207,436	198,866	189,291	599,758	507,031	314,246	286,219	213,552	889,926	803,848
	(b) Other operating income	2,363	1,904	504	5,911	3,738	2,370	1,903	504	5,919	6,131
	Total income from operations (net)	209,799	200,770	189,795	605,669	510,769	316,616	288,122	214,056	895,845	809,979
2	Expenses										
	(a) Cost of material consumed	98,365	98,250	88,028	288,000	248,425	113,129	100,566	90,294	309,046	254,153
	(b) Purchase of stock-in-trade	179	735	6,424	1,462	8,737	45,213	46,058	9,155	137,570	17,166
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,216	(6,140)	(4,648)	(5,527)	2,865	(4,488)	(20,155)	(9,677)	(28,230)	(498)
	(d) Employee benefits expense	17,262	15,962	13,347	48,024	37,657	36,801	33,697	21,343	101,335	59,830
	(e) Depreciation and amortisation expense	5,955	5,954	4,719	18,249	14,015	6,726	8,985	7,597	24,794	22,451
	(f) Provision for decline in the value of long-term investment	-	-	-	-	2,500	-	-	-	-	-
	(g) Other expenses	36,438	32,105	28,662	98,714	79,748	64,744	64,235	38,561	185,371	107,361
	Total expenses	159,415	146,866	136,532	448,922	393,947	262,125	233,386	157,273	729,886	460,463
3	Profit/(loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	50,384	53,904	53,263	156,747	116,822	54,491	54,736	56,783	165,959	148,028
4	Other income	1,171	1,865	1,313	3,605	1,805	3,592	2,729	356	7,402	1,259
5	Profit/(loss) from ordinary activities before finance costs, foreign exchange (gain)/loss and exceptional items (3+4)	51,555	55,769	54,576	160,352	118,627	58,083	57,465	57,139	173,361	184,352
6	Finance costs (refer note 6)	1,485	1,379	1,745	4,249	5,787	2,189	2,097	2,374	6,171	7,371
7	Foreign exchange (gain)/loss (refer note 6)	1,086	4,416	(2,021)	4,855	19,770	2,020	4,202	(208)	6,080	23,862
8	Profit/(loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	48,984	49,974	54,852	151,248	93,070	53,874	51,166	54,973	161,110	153,252
9	Exceptional item	-	-	-	-	-	-	-	-	-	-
10	Profit/(loss) from ordinary activities before tax (8-9)	48,984	49,974	54,852	151,248	93,070	53,874	51,166	54,973	161,110	153,252
11	Tax expense/(credit)	9,557	10,808	13,036	33,315	18,921	15,634	14,043	13,361	44,320	36,345
12	Net Profit/(Loss) for the period (10-11)	39,427	39,166	41,816	117,933	74,149	38,240	37,123	41,612	116,790	116,907
13	Minority interest	-	-	-	-	-	(195)	(95)	(137)	(406)	(378)
14	Net Profit/(Loss) after taxes and minority interest (12-13)	39,427	39,166	41,816	117,933	74,149	38,435	37,218	41,749	117,196	117,285
15	Paid-up Equity Share Capital (Face value Re. 1 per share)	2,915	2,915	2,912	2,915	2,912	2,915	2,912	2,915	2,915	372,100
16	Reserves excluding Revaluation Reserve	13.52	13.44	14.36	40.46	25.46	13.19	12.77	14.34	40.21	23.04
17	Earnings per share of Re.1/- each (not annualised)	13.52	13.42	14.34	40.42	25.43	13.17	12.76	14.32	40.16	23.01
	(a) Basic										
	(a) Diluted										




PART II

SELECT INFORMATION FOR THE QUARTER & NINE MONTHS ENDED 31.12.2014

Particulars	Three months ended			Nine months ended		Year Ended 31.03.2014
	31.12.2014	30.09.2014	31.12.2013	31.12.2014	30.12.2013	
A						
1 PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
- Number of Shares	133,888,935	133,771,235	131,834,694	133,888,935	131,834,694	132,281,235
- Percentage of Shareholding	45.94	45.90	45.27	45.94	45.27	45.39
2 Promoters and promoter group Shareholding						
a) Pledged/Encumbered						
- Number of Shares	13,490,000	14,400,000	34,931,797	13,490,000	34,931,797	29,856,797
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	8.56	9.13	21.92	8.56	21.92	18.76
- Percentage of Shares (as a % of the total share capital of the company)	4.63	4.94	12.00	4.63	12.00	10.24
b) Non-encumbered						
- Number of Shares	144,085,786	143,285,786	124,444,799	144,085,786	124,444,799	129,318,989
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	91.44	90.87	78.08	91.44	78.08	81.24
- Percentage of Shares (as a % of the total share capital of the company)	49.43	49.16	42.73	49.43	42.73	44.37

Particulars	Three months ended	
	31.12.2014	
B		
INVESTOR COMPLAINTS		
Pending at the beginning of the quarter	1	
Received during the quarter	39	
Disposed of during the quarter	40	
Remaining unresolved at the end of the quarter	Nil	



28



NOTES:


- 1 The above unaudited financial results for the quarter and nine months ended December 31, 2014 as reviewed by the Audit Committee have been approved by the Board at its meeting held on February 04, 2015. A Limited Review of the stand alone financial results for the quarter ended December 31, 2014 has been carried out by the Statutory Auditors.
- 2 The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and a Joint Venture.
- 3 The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- 4 Sales of standalone for the current quarter include exports Rs.167,536 lakhs (Quarter ended December 31, 2013: Rs.143,682 lakhs).
- 5 Net sales for the current quarter include dossier income in standalone of Rs.64 lakhs (December 31, 2013:Rs.98 lakhs) and in consolidated of Rs.208 lakhs (December 31, 2013:Rs.167 lakhs).
- 6 Foreign exchange (gain)/loss for stand alone and consolidated includes exchange difference of Rs.4,635 lakhs, 6,657 lakhs, for three months ended December 31, 2014, September 30, 2014, and December 31, 2013 respectively and Rs.12,341 lakhs, Rs.15,164 lakhs for the nine months ended December 31, 2014 and December 31, 2013 respectively, and Rs.20,222 lakhs for the year ended March 31,2014 arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of "AS 16" on Borrowing costs.
- 7 The Board of Directors at their meeting held on September 13, 2013 decided to transfer its injectable unit of the Company on a going concern basis comprising assets and liabilities pertaining to the said unit to its wholly owned subsidiary Curepro Parenterals Limited w.e.f. April 1, 2014. The same is subject to requisite consent, approval or permission of the statutory or regulatory authorities. Pending such approvals, no effect of this scheme has been given in the above results.
- 8 Pursuant to the requirements of Schedule II to the Companies Act, 2013, the management of the Company had reassessed the useful lives of fixed assets held as at April 1, 2014. Based on such internal technical reassessment the Company has accounted for additional depreciation amounting to Rs.1,035 lakhs and Rs.1,158 lakhs for three months ended December 31, 2014 and September 30, 2014 respectively and Rs.3,916 lakhs for the nine months ended December 31, 2014 in standalone and Rs.1,225 lakhs and Rs.1,245 lakhs for three months ended December 31,2014 and September 30, 2014 respectively and Rs. 4,183 lakhs for the nine months ended December 31, 2014 in consolidated results. Further based on transitional provisions, an amount of Rs.1,857 lakhs (net of deferred tax) has been adjusted with stand alone and consolidated opening retained earnings.
- 9 During the quarter, (i) Aurex B.V., The Netherlands, a step down subsidiary of the Company has been incorporated (ii) Natrol LLC, USA has become a step down subsidiary of the Company. (iii) Aurovitas SL, Spain was ceased to be a step down subsidiary of the Company. (iv) Aurobindo Pharma France SARL, France, a step down subsidiary of the Company was merged with Arrow Generiques SAS, France another step down subsidiary of the Company. (v) The ownership of APL Swift Services (Malta) Ltd, a step down subsidiary of the Company was transferred from APL Holdings (Jersey) Limited, to Aurobindo Pharma (Malta) Limited another step down subsidiary of the Company.
- 10 During the current year, on April 1, 2014, Company's European subsidiary Agile Pharma B.V., Netherlands, has acquired select Western European business of Actavis. The above Consolidated results for the quarter and nine months ended December 31, 2014 and quarter ended September 30, 2014 includes the financial results of operations of the above business of Actavis from April 01, 2014. The corresponding figures of the previous periods are not comparable.
- 11 During the current year, on December 4, 2014, Company's USA subsidiary Aurobindo Pharma USA Inc. has acquired Natrol LLC, USA. The above Consolidated results for the quarter and nine months ended December 31, 2014 includes financial results of operations of Natrol LLC, USA from December 4, 2014. The corresponding figures of the previous periods are not comparable.
- 12 On 17th January, 2015 the Company has made allotment of 331,200 equity shares of Re.1/- each at a premium of Rs.90.60 per equity share to the employees under Employee Stock Option Plan 2006. Consequently to the allotment the paid up share capital of the Company has increased to 291,795,921 equity shares of Re.1/- each
- 13 The Board has approved a second interim dividend @200% on the equity share capital of the Company i.e. Rs.2/- per share. This is in addition to interim dividend @150% on equity share capital of the Company i.e. Rs.1.50 per share paid in September, 2014 for the year 2014-15.
- 14 Previous period/year figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N.Govindarajan
Managing Director

www.aurobindo.com

Place: Hyderabad
Date :February 4, 2015




Limited Review Report**Review Report to
The Board of Directors
Aurobindo Pharma Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Aurobindo Pharma Limited ('the Company') for the quarter ended December 31, 2014 (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", [specified under the Companies Act, 1956 (which are deemed to be applicable as per section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014)] and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP**Chartered Accountants****ICAI Firm registration number: 101049W****per Vikas Kumar Pansari**

Partner

Membership No.: 093649



Place: Hyderabad

Date: February 04, 2015